FRPT ends the week with a sharp recovery that puts its bearish positioning under fresh scrutiny — the stock is up 11% in five sessions to $59.12, even as shorts hold nearly one-fifth of the float and BofA trimmed its target this morning.
The positioning picture has barely budged despite the price move. Short interest remains at 19.2% of the free float — roughly 9.4 million shares — essentially unchanged from last week's note. The month-long rebuild from 7.5 million shares to above 10 million in early June, before a slight easing, still defines the bearish side of the ledger. What has shifted is the options market. The put/call ratio has compressed further to 0.58, now 1.2 standard deviations below its 20-day average of 0.84. That keeps options sentiment firmly in the bullish camp, even if the signal is less extreme than the 2.5-standard-deviation reading from a week ago. The borrow market offers no urgency for shorts to cover: availability is ample at 391% of short interest, and the cost to borrow has eased to 0.42% — down 9% over the week and 16% over the past month. There is no mechanical pressure forcing positions to close.
The Street is where the tension sharpens. B of A's Bryan Spillane lowered his price target this morning from $75 to $70, maintaining a Neutral rating — a modest trim but symbolically meaningful given the stock's 11% weekly run. The consensus mean target is $81.63, implying roughly 38% upside from current levels, but the range is wide. Stifel and DA Davidson both carry Buy ratings with targets above $78, while BofA, Jefferies, and Deutsche Bank each hold cautious ratings with targets clustered in the $62–$70 range. JP Morgan upgraded to Overweight in early May with a $68 target — now below the current price — suggesting the stock has already absorbed much of that upgrade's implied move. The bull case rests on distribution expansion and product differentiation in refrigerated pet food; bears point to competitive pressure from The Farmer's Dog and Blue Buffalo relaunches, plus promotional intensity eating into margins. On valuation, the stock trades at a P/E of 30x and EV/EBITDA of 12x — neither extreme, but both have drifted lower over the past seven days as the price recovered faster than estimates.
Factor scores tell a story of excellent fundamental delivery against weak short-side positioning. The EPS surprise rank is in the 99th percentile — FRPT has consistently beaten estimates — and 90-day EPS momentum ranks at the 93rd percentile. The short score of 63.3 has been remarkably stable all week, barely moving despite the price surge, which itself is notable: a stock up 11% in a week with 19% short interest and a flat short score suggests neither forced covering nor fresh conviction on either side. The ORTEX short score rank of just 8 confirms this is a heavily watched name from a bearish perspective relative to the broader universe.
CEO William Cyr sold roughly $2.4 million in shares across May 20–22, when the stock was trading near $47–$51. Those sales look like planned disposals given the range of transaction sizes, and with the stock now at $59, they have aged poorly for the seller. The net insider flow over 90 days is positive in shares but that reflects the sheer size of Cyr's existing holding; no meaningful purchases have followed.
The next earnings event is scheduled for August 3. The prior two prints produced divergent reactions: a modest 2% gain the day after the June 10 event, and a sharp 7% drop followed by a 19% five-day decline after the May 6 release. That asymmetry — one quarter of pain, one of relief — is the backdrop against which this week's rally and persistent short interest need to be read. Whether the 11% move has pre-empted an upgrade cycle or merely squeezed a portion of the short base is the question the August print will begin to answer.
See the live data behind this article on ORTEX.
Open FRPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.